S&P 500   4,471.37
DOW   35,294.76
QQQ   368.94
S&P 500   4,471.37
DOW   35,294.76
QQQ   368.94
S&P 500   4,471.37
DOW   35,294.76
QQQ   368.94
S&P 500   4,471.37
DOW   35,294.76
QQQ   368.94

Genetic Signatures Stock Forecast, Price & News

Today's Range N/A
50-Day Range N/A
52-Week Range N/A
Average VolumeN/A
Market CapitalizationN/A
P/E RatioN/A
Dividend YieldN/A

Receive GSS News and Ratings via Email

Sign-up to receive the latest news and ratings for Genetic Signatures and its competitors with MarketBeat's FREE daily newsletter.

About Genetic Signatures

Genetic Signatures Limited operates as a molecular diagnostic (MDx) company in North America and Australia. The company designs and manufactures a suite of real-time polymerase chain reaction based products for detection of infectious diseases under EasyScreen brand name. It also provides MDx 3Base platform technology that enables hospital and pathology laboratories to screen for a range of infectious pathogens. Genetic Signatures Limited was founded in 2001 and is headquartered in Sydney, Australia.


No headlines for this company have been tracked by MarketBeat.com

Industry, Sector and Symbol

Diagnostics & Research
Year Founded

Sales & Book Value

Annual Sales
$28.38 million
Book Value
A$0.35 per share





Next Earnings Date


Overall MarketRank

0.00 out of 5 stars

Analyst Opinion: 0.0Community Rank: 0.0Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -

Genetic Signatures (ASX:GSS) Frequently Asked Questions

What stocks does MarketBeat like better than Genetic Signatures?

Wall Street analysts have given Genetic Signatures a "N/A" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Genetic Signatures wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

Who are Genetic Signatures' key executives?

Genetic Signatures' management team includes the following people:
  • Dr. John R. Melki, MD, CEO & Exec. Director
  • Mr. Peter Manley, CFO & Company Sec.
  • Mr. Michael Anton Aicher M.B.A., BSc, MBA, Exec. Director of US Operations & Exec. Director (Age 61, Pay $178.1k)
  • Mr. Christopher M. Abbott, Founder & Chairman Emeritus
  • Dr. Douglas S. Millar BSc, Ph.D., Chief Scientific Officer
  • Mr. Jackson Jones, Director of Global Sales & Marketing
  • Mr. Patrick Noland BSc, MBA, US Market Consultant

What is Genetic Signatures' stock symbol?

Genetic Signatures trades on the ASX under the ticker symbol "GSS."

How much money does Genetic Signatures make?

Genetic Signatures has a market capitalization of $0.00 and generates $28.38 million in revenue each year.

How many employees does Genetic Signatures have?

Genetic Signatures employs 1,626 workers across the globe.

What is Genetic Signatures' official website?

The official website for Genetic Signatures is www.geneticsignatures.com.

Where are Genetic Signatures' headquarters?

Genetic Signatures is headquartered at 333 Bay Street, Toronto, Ontario M5H 2T6.

How can I contact Genetic Signatures?

Genetic Signatures' mailing address is 333 Bay Street, Toronto, Ontario M5H 2T6. The company can be reached via phone at 61 2 9870 7580.

This page was last updated on 10/16/2021 by MarketBeat.com Staff


Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.